Morphogeneis Inc. Archives

Positive Results in Cancer Vaccine Trial for Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Morphogenesis, Inc., a biotechnology company focused on developing cancer vaccines, in partnership with CohBar, believes they have met their milestone with IFx-HU2.0, a cancer vaccine studied in advanced Merkel cell carcinoma and squamous cell carcinoma.

Tampa’s Morphogenesis Wants To Cure Cancer With an Affordable Shot

A group of scientists in Tampa is working to make treating cancer as easy as getting a shot. While most of today's cancer treatments tend to be toxic and expensive, UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc., a clinical-stage biotechnology company, is working to develop immunotherapies that are safe and affordable.

Experimental Skin Cancer Vaccine Developed in Tampa Saves Woman’s Life

A vaccine developed by Morphogenesis, Inc., a UF startup and UF Innovate | Sid Martin Biotech alum, helped improve a patients condition.

Morphogenesis Awarded SBIR Funding for Cervical Cancer Therapy

UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc., a clinical-stage biotechnology company, has obtained funding to develop a new therapeutic drug to treat cervical cancer.

Morphogenesis’ Skin Cancer Vaccine Gets FDA ‘Fast Track’

Tampa company Morphogenesis, a UF startup, has received a “fast track” designation for its skin cancer vaccination from the United States Food and Drug Administration.

Tampa Company Developing Cancer Vaccines Could Receive Grant To Research Cervical Cancer Vaccine

UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc., a Tampa-based company that has been researching and developing a vaccine for certain types of skin cancers, could be soon receiving a grant to begin research on a cervical cancer treatment for underprivileged women.

Skin Cancer Vaccine Developed by Tampa Company Enters Phase 1 of Clinical Trial

UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc. completed its first-in-human phase one trial in cutaneous melanoma at Moffitt Cancer Center within the past year and has now moved into studying patients in earlier stages of skin cancers.

Morphogeneis Inc.